Newsletter - July 2014
Focus on Unmet Clinical Needs:
Familial Hypercholesterolaemia (FH)
From the Editors: Missing FH - How can we improve FH referral and diagnosis?
According to Prof. Raul Santos, Lipid Clinic Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil, light is starting to appear at the end of the FH tunnel...
Improving FH detection in primary care: UK Medway CCG FH Audit Programme warrants wider rollout
PCSK9: Opportunities for personalised medicine in FH?
Dr. Marina Cuchel, University of Pennsylvania, Philadelphia, USA comments on new data showing that PCSK9 gain of function mutations are relatively common in FH patients in Japan.
State of the Science: The FH enigma - Does whole exome sequencing provide insights?
Exclusive interviews
FH management in low- to middle-income countries
Dr. Dirk Blom, University of Cape Town, South Africa, provides a perspective
Hot Topics
How low should LDL-C be lowered: Thoughts of IMPROVE-IT put this back on the agenda
Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite linkOur mission
Our goal
In the next 3 years the PCSK9 Education and Research Forum will become a major, globally-recognised source of independent, scientific knowledge of the critical importance of PCSK9 inhibition in the search for treatments which promise to transform the prognosis of millions of people with atherosclerotic dyslipidaemia.
Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.
Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes. |
|
|
